Intro to lipids & lipoproteins: why there is no ‘bad’ or ‘good’ cholesterol
I recently posted on Twitter about my frustration with the way the press writes about “good” and “bad” cholesterol, and…
Coronary atherosclerosis is a silent killer, but we have tools to stop it
A new study reveals that the prevalence of atherosclerosis is alarmingly high among asymptomatic adults classified as “low risk” and underscores the importance of lipid-lowering therapies for avoiding atherosclerosis progression and mortality
#311 ‒ Longevity 101: a foundational guide to Peter’s frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more
“I would say three-quarters of the benefits you can get towards a longer life, come solely from pursuing better health.” —Peter Attia
#306 – AMA #60: preventing cognitive decline, nutrition myths, lowering blood glucose, apoB, and blood pressure, and more
“Metabolic health, first and foremost, is the goal of nutrition.” —Peter Attia
“The cholesterol paradox”: a catchy phrase for an idea with no substance
A recent study reported that hypercholesterolemia is associated with reduced mortality, but it falls short of upsetting conventional wisdom
The genetics of PCSK9i nonresponders
A recent case study shines light on why some individuals are resistant to PCSK9 inhibitors.
Heart Disease: Labs & Diagnostic Tests
This video clip is from episode #203 — AMA #34: What causes heart disease? — originally released on April 18,…
First Case of Human PCSK9 Gene-Editing
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
Cumulative effects of LDL-C reduction in mitigating cardiovascular risk
Atherosclerotic cardiovascular disease (ASCVD) is currently the leading cause of death in the U.S. One of the most effective ways to reduce risk of ASCVD mortality is reduction of apoB particle number, typically estimated by LDL cholesterol (LDL-C) concentrations.
Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…